Live Breaking News & Updates on Corticosteroid taper

FDA Approves First Biologic Treatment for Polymyalgia Rheumatica

The interleukin-6 receptor antagonist sarilumab (Kevzara) will be indicated in adults who have had an inadequate response to corticosteroids or could not tolerate a corticosteroid taper.

Georged-yancopolous , Drug-administration , American-college-of-rheumatology , Medscape-medical-newspreviously , Rheumatoid-arthritis , A , Biologic-therapy , Corticosteroid , Corticosteroid-taper , Polymyalgia-rheumatica , Neutropenia